Compagnie Lombard Odier SCmA Sells 16,473 Shares of DexCom, Inc. (NASDAQ:DXCM)

Compagnie Lombard Odier SCmA cut its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 10.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 134,810 shares of the medical device company's stock after selling 16,473 shares during the period. Compagnie Lombard Odier SCmA's holdings in DexCom were worth $10,484,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of DXCM. Versant Capital Management Inc bought a new position in DexCom in the 4th quarter valued at $25,000. Riverview Trust Co boosted its position in DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock valued at $31,000 after buying an additional 232 shares during the last quarter. Heck Capital Advisors LLC bought a new position in DexCom in the 4th quarter valued at $38,000. MassMutual Private Wealth & Trust FSB boosted its position in DexCom by 46.7% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company's stock valued at $65,000 after buying an additional 265 shares during the last quarter. Finally, RPg Family Wealth Advisory LLC bought a new position in DexCom in the 3rd quarter valued at $57,000. 97.75% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

DXCM has been the topic of a number of recent research reports. Sanford C. Bernstein increased their price objective on DexCom from $82.00 to $86.00 and gave the company an "outperform" rating in a research report on Friday, October 25th. Canaccord Genuity Group increased their price target on DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a research note on Friday. JPMorgan Chase & Co. increased their price target on DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a research note on Friday, October 25th. Wells Fargo & Company increased their price target on DexCom from $90.00 to $94.00 and gave the company an "overweight" rating in a research note on Wednesday, December 11th. Finally, Oppenheimer cut their price target on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research note on Friday, October 25th. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $99.06.

DexCom Stock Up 1.6 %

DXCM stock traded up $1.46 during trading hours on Tuesday, reaching $90.53. 5,693,359 shares of the stock were exchanged, compared to its average volume of 3,651,431. The firm's 50-day moving average is $82.65 and its 200-day moving average is $75.62. The company has a market cap of $35.36 billion, a price-to-earnings ratio of 54.21, a PEG ratio of 2.26 and a beta of 1.14. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 31.40% and a net margin of 17.22%. On average, equities research analysts expect that DexCom, Inc. will post 1.69 earnings per share for the current year.

Insiders Place Their Bets

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares in the company, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the transaction, the chief operating officer now owns 268,644 shares of the company's stock, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 42,342 shares of company stock worth $3,628,069. Corporate insiders own 0.30% of the company's stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.